Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)
Stefano Cavalieri(University of Milan), Lisa Licitra(University of Milan), Annalisa De Silvestri(Policlinico San Matteo Fondazione), Virginia Valeria Ferretti(University of Pavia), Filippo de Braud(University of Milan), Francesco Agustoni(University of Pavia), Angelica Facoetti(University of Pavia), Sara Ronchi(National Center for Oncological Hadrontherapy), Marco Durante(GSI Helmholtz Centre for Heavy Ion Research), Claudia Fournier(GSI Helmholtz Centre for Heavy Ion Research), Chiara Campo(National Center for Oncological Hadrontherapy), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Catherine Klersy(Policlinico San Matteo Fondazione), Viviana Vitolo(National Center for Oncological Hadrontherapy), Amelia Barcellini(University of Pavia), Marco Platania(Fondazione IRCCS Istituto Nazionale dei Tumori), Ester Orlandi(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Alexander Helm(GSI Helmholtz Centre for Heavy Ion Research), Silvia Molinelli(National Center for Oncological Hadrontherapy)
Cited by 20
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k